Back to Results
First PageMeta Content
Alkylating antineoplastic agents / Acute leukemia / Acute myeloid leukemia / Myeloid leukemia / Myelodysplastic syndrome / Carboplatin / Chemistry / Oncology / Medicine


April 10, 2013 Astex Pharmaceuticals Provides SGI-110 Update Oral Presentation at AACR Supports Potential of SGI-110 In The Treatment Of Platinum-Resistant Ovarian Cancer Clinical Update on SGI[removed]Study DUBLIN, Cali
Add to Reading List

Open Document

File Size: 24,39 KB

Share Result on Facebook

City

Washington / DC / DUBLIN / /

Company

Astex Pharmaceuticals Inc. / Astex Pharmaceuticals Astex Pharmaceuticals / /

Event

FDA Phase / /

Facility

Indiana University / /

IndustryTerm

Treatment Of Platinum-Resistant Ovarian Cancer / pharmaceutical / /

MedicalCondition

tumor / ovarian cancer / significantly delayed tumor / Cancer / myelodysplastic syndromes / platinum-resistant ovarian cancer / silenced tumor / several tumor / established ovarian cancer / platinum-resistant recurrent ovarian cancer / acute myeloid leukemia / /

MedicalTreatment

chemotherapy / /

Organization

American Society of Hematology / Association of Cancer Research / American Society of Clinical Oncology / Indiana University / /

Position

clinical investigator / /

Product

carboplatin / paclitaxel / DACOGEN / SGI-110 / SGI-110-02 / presentation / SGI-110-01 / MDS / /

ProvinceOrState

California / /

PublishedMedium

Cancer Research / /

Technology

gene expression / chemotherapy / /

URL

http /

SocialTag